RxDoctor Payments Data

Lauren Hock, MD

Ophthalmology · Philadelphia, PANPI 1750810164

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 27 payments — averaging $59.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$775
  • AbbVie$212
  • Alcon$156
  • NEW World Medical,inc.$141
  • Novartis$124
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$107
  • plus $96 from 3 others

What the payments were for

  • Food & beverage$1,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$199,699
Medicare patients
371
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate143$78,363
LumiganBimatoprost119$48,029
VyzultaLatanoprostene Bunod64$27,283
RocklatanNetarsudil Mesylat/Latanoprost63$25,856
SimbrinzaBrinzolamide/Brimonidine Tart90$21,219
Brimonidine Tartrate473$14,225
Alphagan PBrimonidine Tartrate40$13,777
Travoprost79$13,762
CombiganBrimonidine Tartrate/Timolol47$13,179
Prednisolone Acetate361$13,110
Latanoprost978$10,954
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$9,556
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat515$9,279
Brinzolamide45$7,351
Methazolamide49$6,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$40$104,219206 claims
AbbVieLumigan, Alphagan P, Combigan$212$74,985206 claims
AlconSimbrinza$156$21,21990 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →